Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis

Kamal Menghrajani, Philip S. Boonstra, Jessica A. Mercer, Cecelia Perkins, Krisstina L. Gowin, Alissa A. Weber, Ruben Mesa, Jason R. Gotlib, Lixia Wang, Jack W. Singer, Moshe Talpaz

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

JAK inhibitors for myelofibrosis (MF) reduce spleen size, control constitutional symptoms, and may improve survival. We studied the clinical characteristics of 548 MF patients treated with JAK inhibitors from 2008 to 2016 to better understand predictors of splenic response. Response was defined as a 50% decrease in spleen size at early (3–4 months on therapy) and late (5–12 months) timepoints after therapy initiation. Early response positively correlated with higher doses of JAK inhibitor, baseline spleen size 5–10 cm, and hemoglobin. Early response negatively correlated with baseline spleen size >20 cm and high WBC. The strongest predictor of late response was whether a patient had a response at the earlier timepoint (OR 8.88). Our response models suggest that clinical factors can be used to predict which patients are more likely to respond to JAK inhibitors, and those who do not achieve an early response, i.e. within 3–4 months, should consider alternative treatments.

Original languageEnglish (US)
Pages (from-to)1036-1042
Number of pages7
JournalLeukemia and Lymphoma
Volume60
Issue number4
DOIs
StatePublished - Mar 21 2019
Externally publishedYes

Keywords

  • JAK inhibitors
  • Myelofibrosis
  • myeloproliferative neoplasms
  • predictive models

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosis'. Together they form a unique fingerprint.

Cite this